In vitro susceptibility of isolates of Sporothrix schenckii to amphotericin B, itraconazole, and terbinafine: Comparison of yeast and mycelial forms

Canadian Journal of Microbiology

Volumn 52, Issue 9, 2006, Pages 843-847

  Kohler, Lidiane Meire ^a   Soares, Betânia Maria ^a   De Assis Santos, Daniel ^a   Da Silva Barros, Maria Elisabete ^a   Hamdan, Júnia Soares ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Antifungal drug; Sporothrix schenckii; Susceptibility testing

Indexed keywords

BIODIVERSITY; DRUG PRODUCTS; MICROBIOLOGY; PROTEINS;

ANTIFUNGAL DRUGS; SPOROTHRIX SCHENCKII; SUSCEPTIBILITY TESTING;

FUNGI;

AMPHOTERICIN B; ITRACONAZOLE; TERBINAFINE;

COMPARATIVE STUDY; DILUTION; FUNGICIDE; FUNGUS; GENETIC ANALYSIS; IMMUNITY; YEAST;

ANTIBIOTIC SENSITIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DILUTION; DOSE RESPONSE; DRUG ACTIVITY; FUNGUS ISOLATION; IN VITRO STUDY; LIQUID CULTURE; MINIMUM INHIBITORY CONCENTRATION; MYCELIUM; NONHUMAN; PRIORITY JOURNAL; SPOROTHRIX SCHENCKII; YEAST;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CATS; DOGS; HORSES; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MYCELIUM; NAPHTHALENES; SPOROTHRIX; YEASTS;

ANIMALIA; SPOROTHRIX SCHENCKII;

EID: 33846179727     PISSN: 00084166     EISSN: None     Source Type: Journal    
DOI: 10.1139/W06-040     Document Type: Article

References (30)

1. Araújo, T., Marques, A.C., and Kerdel, F. 2001. Sporotrichosis. Int. J. Dermatol. 40: 737-742.
2. Casali, A.K., and Hamdan, J.S. 1997. Effect of three azole derivatives on the lipids of different strains of Sporothrix schenckii. Can. J. Microbiol. 43: 1197-1202.
3. -1) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses, 47: 62-68.
4. Clinical Laboratory Standards Institute. 2002a. Reference method for broth dilution antifungal susceptibility testing of yeast: approved standard M27-A2. National Committee for Clinical Laboratory Standard, Wayne, Pa.
5. Clinical Laboratory Standards Institute. 2002b. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard M38-A. National Committee for Clinical Laboratory Standards. Wayne, Pa.
6. Espinel-Ingroff, A. 1998a. Comparison of in vitro activities of the new triazole SCH56592 and echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36: 2950-2956.
7. Espinel-Infroff, A. 1998b. In vitro activity of the new triazole voriconazole (UK 109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36: 198-202.
8. Gehrt, A., Peter, J., Pizzo, P.A., and Walsh, T.J. 1995. Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs antifungal agents by broth microdilution methods. J. Clin. Microbiol. 33: 1302-1307.
9. Ghosh, A., Chakrabarti, A., Hemashettar, B.M., and Maiti, P.K. 2001. In vitro susceptibility pattern of Sporothrix schenckii strains isolated from three centers in India. Indian J. Med. Res. 113: 214-220.
10. Hahn, R.C., Fontes, C.J.F., Batista, R.D., and Hamdan, J.S. 2002. In vitro comparison of activities of terbinafine and itraconazole against Paracoccidioides brasiliensis. J. Clin. Microbiol. 40: 2828-2831.
11. Hamdan, J.S., and Casali, A.K. 1996. Effect of amphotericin B on the lipids of yeast cells of Sporothrix schenckii. Mycopathologia, 136: 125-131.
12. Hay, R.J. 1999. Therapeutic potential of terbinafine in subcutaneous and systemic mycoses. Br. J. Dermatol. 141(Suppl. 56): 36-40.
13. Jessup, C.J., Ryder, N.S., and Ghannoum, M.A. 2000. An evaluation of the in vitro activity of terbinafine. Med. Mycol. 38: 155-159.
14. Kan, V.L., and Bennett, J.E. 1988. Efficacies of four antifungal agents in experimental murine sporotrichosis. Antimicrob. Agents Chemother. 32: 1619-1623.
15. Kauffman, C.A., Hajjeh, R., and Chapman, S.W. 2000. Practice guidelines for the management of patients with sporotrichosis. Clin. Infect. Dis. 30: 684-687.
16. Koç, A.N., Uksa, U., and Oymak, O. 2001. Case report. Successfully treated subcutaneous infection with Sporothrix schenckii in Turkey. Mycoses, 43: 75-77.
17. Kohler, L.M., Monteiro, P.C.F., Hahn, R.C., and Hamdan, J.S. 2004. In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine. J. Clin. Microbiol. 42: 4319-4320.
18. Lortholary, O., Denning, D.W., and Dupont, B. 1999. Endemic mycoses: a treatment update. J. Antimicrob. Chemother. 43: 321-331.
19. McGinnis, M.R., Pasarell, L., Sutton, D.A., Fothergill, A.W., Cooper, C.R., and Rinaldi, M.G. 1997. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob. Agents Chemother. 41: 1832-1834.
20. McGinnis, M.R., Nordoff, N., Li, R.K., Pasarell, L., and Warnock, D.W. 2001. Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B. Med. Mycol. 39: 369-371.
21. Morris-Jones, R. 2002. Sporotrichosis. Clin. Exp. Dermatol. 27: 427-431.
22. Nakai, T., Uno, J., Ikeda, F., Tawara, S., Nishimura, K., and Miyaji, M. 2003. In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeastlike and mycelial forms. Antimicrob. Agents Chemother. 47: 1376-1381.
23. Noguchi, H., Hiruma, M., and Kawada, A. 1999. Case report. Sporotrichosis successfully treated with itraconazole in Japan. Mycoses, 42: 571-576.
24. Odabasi, Z., Paetznick, V.L., Rodriguez, J.R., Chen, E., and Zeichner, L.O. 2004. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob. Agents Chemother. 48: 1912-1915.
25. Pena, C., Garcia-Silva, J., Varela, J., Ardavin, M., and Pereiro, M., Jr. 1999. Esporotricosis cutanea atipica. Respuesta a itraconazol y cirugia. Acta Otorrinolaringol. Esp. 50: 485-489.
26. Ryder, N.S. 1999. Activity of terbinafine against serious fungal pathogens. Mycoses, 42(Suppl. 2): 115-119.
27. Shadomy, S., Espinel-Ingroff, A., and Cartwright, R.Y. 1987. Estudios de laboratorio con agentes antifungicos: pruebas de susceptibilidad y bioensayos. In Manual de microbiologia clinica. 4th ed. Edited by E.H. Lennette, A. Balows, W.J. Hausler, and H.J. Shadomy. Editorial Medica Panamericana, Buenos Aires, Argentina. pp. 1229-1238.
28. Tanuma, H., Hiramatsu, M., Mukai, H., Ab, M., Kume, H., Nishiyama, S., and Katsuoka, K. 2000. Case report: a case of chromoblastomycosis effectively treated with terbinafine. Characteristics of chromoblastomycosis in the Kitasato region, Japan. Mycoses, 43: 79-83.
29. Trilles, L., Torres, B.F., Lazera, M.S., Wanke, B., Schubach, A.O., Paes, R.A., Inza, I., and Guarro, J. 2005. In vitro antifungal susceptibility of Sporothrix schenckii in two growth phases. Antimicrob. Agents Chemother. 49: 3952-3954.
30. White, T.C., Mar, K.A., and Bowden, R.A. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11: 382-402.